Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers

RadioMedix and Orano Med announced the initiation of the Phase II clinical trial of AlphaMedix™ with the treatment of the first patient on December 21st, 2021. This trial will evaluate the safety and effectiveness of ²¹²Pb-DOTAMTATE (AlphaMedix™) in Peptide Receptor Radionuclide Therapy (PRRT) of naive patients with somatostatin receptor-expressing neuroendocrine tumors (NET).

To read more please visit:

Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers

Source: Radio Medix